| Company Name: | AmerisourceBergen Corp | | Ticker Symbol: | ABC | | | WWW Address: | www.amerisourcebergen.net |
| CEO: | Steven H. Collis | | No. of Employees: | 13,400 |
| Common Issue Type: | CS | | Business Description: | AmerisourceBergen Corporation is a pharmaceutical services company providing drug distribution and related healthcare services and solutions to pharmacy, physician, and manufacturer customers, which are based mainly in the United States and Canada.
|
| | | Industry Information: | WHOLESALE - Drugs Wholesale [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 54.99 |  0.59 | - | - | 54.44 | 55.07 | 54.18 | 2180967 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 12,697.6 | 230.9 | 0.74 | 2.80 | 0.52 | 24.0 | 1.5 | 56.91 - 35.98 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 54.99 | $ | | PE Ratio - LTM | 24.0 | |
| Market Capitalisation | 12,697.6 | mil |
| Latest Shares Outstanding | 230.9 | mil |
| Earnings pS (EPS) | 2.80 | $ |
| Dividend pS (DPS) | 0.52 | ¢ |
| Dividend Yield | 1.5 | % |
| Dividend Payout Ratio | 19 | % |
| Revenue per Employee | 5,932,059 | $ |
| Effective Tax Rate | 39.1 | % |
| Float | 229.5 | mil |
| Float as % of Shares Outstanding | 99.8 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 1.60 | % |
| Research & Devlopment (R&D) as % of Revenue | 0.00 | % |
| Gross Profit Margin | 3.4 | % |
| EBITDA Margin | 1.8 | % |
| Pre-Tax Profit Margin | 1.4 | % |
| Assets Turnover | 5.1 | % |
| Return on Assets (ROA) | 3.5 | % |
| Return on Equity (ROE) | 23.8 | % |
| Return on Capital Invested (ROCI) | 14.9 | % |
| Current Ratio | 1.0 | |
| Leverage Ratio (Assets/Equity) | 6.9 | |
| Interest Cover | 14.2 | |
| Total Debt/Equity (Gearing Ratio) | 0.60 | |
| LT Debt/Total Capital | 37.0 | % |
| Working Capital pS | -1.38 | $ |
| Cash pS | 5.83 | $ |
| Book-Value pS | 10.16 | $ |
| Tangible Book-Value pS | -5.05 | $ |
| Cash Flow pS | 3.10 | $ |
| Free Cash Flow pS | 2.32 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 5.41 | |
| Price/Tangible Book Ratio | -10.89 | |
| Price/Cash Flow | 17.7 | |
| Price/Free Cash Flow | 23.7 | |
| P/E as % of Industry Group | 128.0 | % |
| P/E as % of Sector Segment | 117.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 05/05/2013 |
| Dividend Ex-Date | 05/15/2013 |
| Dividend Record Date | 05/19/2013 |
| Dividend Pay Date | 06/02/2013 |
| Dividend Amount | 210 |
| Type of Payment | Cash Payment |
| Dividend Rate | 0.84 |
| Current Dividend Yield | 1.5 |
| 5-Y Average Dividend Yield | 1.1 |
| Payout Ratio | 19.0 |
| 5-Y Average Payout Ratio | 16.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.3 | 98 | 20,256 | 110,812 |
| 4 Weeks | 56.91 | 52.78 | 55.92 | -1.7 | 92 | 26,759 | 535,186 |
| 13 Weeks | 56.91 | 46.08 | 46.60 | 18.0 | 108 | 25,937 | 1,634,029 |
| 26 Weeks | 56.91 | 40.37 | 40.26 | 36.6 | 111 | 24,569 | 3,046,518 |
| 52 Weeks | 56.91 | 35.98 | 35.99 | 52.8 | 119 | 25,048 | 6,236,981 |
| YTD | 56.91 | 43.01 | - | 27.4 | 109 | 24,471 | 2,324,722 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 54.77 | 54.80 | 52.90 | 46.93 | 44.55 | 0.74 | 0.66 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 3.33 | 88.1 | 1.46 |
| Income | 22.21 | 66.0 | 6.41 |
| Dividend | 35.30 | 98.6 | 26.47 |
| Capital Spending | 15.52 | NA | 76.89 |
| R&D | 0.00 | NA | 0.00 |
| Normalized Inc. | 15.69 | NA | 10.02 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 2.8 | 2.3 | -0.9 |
| Earnings % | -42.7 | -78.5 | 1.7 |
| EPS % | -35.9 | -76.5 | 10.2 |
| EPS $ | -0.51 | -0.62 | 0.26 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | -1.47 |
| Current Ratio | 1.0 |
| Quick Ratio (Acid Test) | 0.4 |
| Liquidity Ratio (Cash) | 0.10 |
| Receivables Turnover | 20.4 |
| Average Collection Period | 18 |
| Working Capital/Equity | -9.3 |
| Working Capital pS | -0.97 |
| Cash-Flow pS | 3.68 |
| Free Cash-Flow pS | 0.99 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 6.01 |
| Financial Leverage Ratio (Assets/Equity) | 6.3 |
| Debt Ratio | 84.1 |
| Total Debt/Equity (Gearing Ratio) | 0.59 |
| LT Debt/Equity | 0.59 |
| LT Debt/Capital Invested | 45.4 |
| LT Debt/Total Liabilities | 11.1 |
| Interest Cover | 13.0 |
| Interest/Capital Invested | 2.30 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 9.39 |
| Tobin's Q Ratio | 0.82 |
| Current P/E Ratio - LTM | 24.00 |
| Enterprise Value (EV)/EBITDA | 17.03 |
| Enterprise Value (EV)/Free Cash Flow | 391.11 |
| Dividend Yield | 1.5 |
| Price/Tangible Book Ratio - LTM | -10.89 |
| Price/Book Ratio - LTM | 5.41 |
| Price/Cash Flow Ratio | 17.7 |
| Price/Free Cash Flow Ratio - LTM | 23.7 |
| Price/Sales Ratio | 0.16 |
| P/E Ratio (1 month ago) - LTM | 24.0 |
| P/E Ratio (26 weeks ago) - LTM | 14.4 |
| P/E Ratio (52 weeks ago) - LTM | 13.7 |
| 5-Y High P/E Ratio | 31.6 |
| 5-Y Low P/E Ratio | 8.0 |
| 5-Y Average P/E Ratio | 16.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 150 |
| P/E as % of Industry Group | 128.0 |
| P/E as % of Sector Segment | 117.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 18.9 |
| PER SHARE FIGURES |
| LT Debt pS | 6.15 |
| Current Liabilities pS | 47.64 |
| Tangible Book Value pS - LTM | -5.05 |
| Book Value pS - LTM | 10.16 |
| Capital Invested pS | 16.90 |
| Cash pS - LTM | 5.83 |
| Cash Flow pS - LTM | 3.10 |
| Free Cash Flow pS - LTM | 2.32 |
| Earnings pS (EPS) | 2.80 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 0.29 |
| Free Cash Flow Margin 5YEAR AVG | 0.80 |
| Net Profit Margin | 0.9 |
| Net Profit Margin - 5YEAR AVRG. | 0.7 |
| Equity Productivity | 32.36 |
| Return on Equity (ROE) | 29.3 |
| Return on Equity (ROE) - 5YEAR AVRG. | 20.6 |
| Capital Invested Productivity | 20.36 |
| Return on Capital Invested (ROCI) | 18.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 14.2 |
| Assets Productivity | 5.20 |
| Return on Assets (ROA) | 4.7 |
| Return on Assets (ROA) - 5YEAR AVRG. | 4.0 |
| Gross Profit Margin | 3.4 |
| Gross Profit Margin - 5YEAR AVRG. | 3.1 |
| EBITDA Margin - LTM | 1.8 |
| EBIT Margin - LTM | 1.5 |
| Pre-Tax Profit Margin | 1.5 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 1.3 |
| Effective Tax Rate | 39.1 |
| Effective Tax Rate - 5YEAR AVRG. | 38.2 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 44 |
| Revenue per Employee | 5,932,059 |
| Net Income per Employee | 53,656 |
| Average Collection Period | 18 |
| Receivables Turnover | 20.4 |
| Day's Inventory Turnover Ratio | 26 |
| Inventory Turnover | 13.8 |
| Inventory/Sales | 7.2 |
| Accounts Payble/Sales | 12.11 |
| Assets/Revenue | 0.19 |
| Net Working Capital Turnover | -349.66 |
| Fixed Assets Turnover | 17.83 |
| Total Assets Turnover | 5.2 |
| Revenue per $ Cash | 74.53 |
| Revenue per $ Plant | 101.91 |
| Revenue per $ Common Equity | 32.36 |
| Revenue per $ Capital Invested | 20.36 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 1.5 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 1.5 |
| Research & Devlopment (R&D) as % of Revenue | 0.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
|
|  
| | |  |  | |
| |
